RB Goldberg, DM Kendall, MA Deeg, JB Buse, … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—We enrolled subjects with a diagnosis of type 2
diabetes (treated with diet alone or oral monotherapy) and dyslipidemia (not
treated with any lipid-lowering agents). After a 4-week placebo washout ... Cited by 334 - Related articles - BL Direct - All 13 versions
RB Goldberg, DM Kendall, MA Deeg, JB Buse, … - diabetezone.it Page 1. Un Confronto tra gli effetti del pioglitazone e del rosiglitazone sulla
glicemia e sui lipidi in pazienti con diabete di tipo 2 e dislipidemia ... Related articles - View as HTML
- ►peoriaendocrine.com [PDF] JA Dormandy, B Charbonnel, DJA Eckland, E … - The Lancet, 2005 - Elsevier We did a prospective, randomised controlled trial in 5238 patients with type 2
diabetes who had evidence of macrovascular disease. We recruited patients from
primary-care practices and hospitals. We assigned patients to oral ... Cited by 1142 - Related articles - BL Direct - All 41 versions
E Chiquette, G Ramirez, R DeFronzo - Archives of internal medicine, 2004 - archinte.highwire.org You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 196 - Related articles - BL Direct - All 6 versions
- ►touchcardiology.com [PDF] T Mazzone, PM Meyer, SB Feinstein, MH … - Jama, 2006 - Am Med Assoc Context Carotid artery intima-media thickness (CIMT) is a marker of coronary
atherosclerosis and independently predicts cardiovascular events, which are
increased in type 2 diabetes mellitus (DM). While studies of relatively ... Cited by 216 - Related articles - BL Direct - All 13 versions
AM Lincoff, K Wolski, SJ Nicholls, SE Nissen - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Pioglitazone is ... Cited by 326 - Related articles - BL Direct - All 7 versions
- ►infodiabetes.it [PDF] S Singh, YK Loke, CD Furberg - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Recent reports of ... Cited by 304 - Related articles - BL Direct - All 12 versions
- ►onlinejacc.org A Pfützner, N Marx, G Lübben, M Langenfeld, … - Journal of the American College of Cardiology, 2005 - Elsevier A total of 192 patients were enrolled into a six-month, prospective, open-label,
controlled clinical study. They were randomized to receive either pioglitazone
(45 mg) or glimepiride (1 to 6 mg, with the intent to optimize therapy). ... Cited by 173 - Related articles - All 18 versions
- ►infodiabetes.it [PDF] PD Home, SJ Pocock, H Beck-Nielsen, R … - New England Journal of Medicine, 2007 - content.nejm.org From Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne,
United Kingdom (PDH); the Med- ical Statistics Unit, London School of Hy- giene
and Tropical Medicine, London (SJP); the Department of Endocrinolo- gy and ... Cited by 496 - Related articles - BL Direct - All 15 versions
- ►ahajournals.org JPH van Wijk, EJP de Koning, EP Martens, TJ … - Arteriosclerosis, thrombosis, and vascular biology, 2003 - Am Heart Assoc We evaluated study population characteristics and treatment effects on blood
lipids between studies in which either rosiglitazone (RSG) or pioglitazone (PIO)
was investigated in patients with type 2 diabetes. We performed a summary ... Cited by 130 - Related articles - BL Direct - All 7 versions
